

# CLARITY

Controlled evaluation of Angiotensin Receptor Blockers for COVID-19 respiratory disease

Issue 4 | 07 September 2020

## Study Overview

CLARITY will establish whether Angiotensin Receptor Blockers (ARBs) can reduce the severity of COVID-19. Pragmatic trial design embedded in routine care to avoid placing additional demands on busy health staff.

## Progress Updates

### India

- IMP labelled in double-blind format packaged and shipped to initiated sites.
- 4 sites initiated, undergoing set up (AIIMS, Raipur, CMC, Ludhiana, Christian Hospital, Nabarangpur & LNJP, Delhi).



### Australia

- 1 participant randomised (RPA Hospital).
- 8 sites activated (Canterbury, Concord, RPA, RNSH, Wollongong, St George, Austin & Prince of Wales Hospitals).
- 7 sites initiated, undergoing set up (RPA Virtual, John Hunter, Westmead, Liverpool, Alfred, Sutherland & Sunshine Hospitals).

## Meet the Research Fellows



### **Dr Sradha Kotwal – CLARITY Co-Scientific Lead & Study Physician**

Sradha is a nephrologist at Prince of Wales in Sydney, a research fellow at TGI Australia and a conjoint senior lecturer at UNSW. She has expertise in implementation research, translation of research into practice and linked data.



### **Mr Abhinav Basso – CLARITY Research Fellow**

Abhinav is a physiotherapist trained in public health, currently working as a Research Fellow at the George Institute for Global Health, India. Diabetes, CKD and mobile health interventions are key areas of his work.



### **Dr Carinna Hockham – CLARITY Co-Scientific Lead**

Carinna is a research fellow at TGI Australia and Conjoint Lecturer at UNSW. Carinna's research involves using novel trial methodologies, including adaptive design, to improve health outcomes in people with chronic disease.

## Relevant Literature Updates

### **BRACE CORONA**

- Trial conducted in Brazil.
- Randomised 659 COVID-19 patients *already* treated with an ARB/ACEI to either suspend their RAASi treatment or continue their RAASi treatment.
- Relatively young and low-risk cohort with low event rate
- No difference in Days Alive and Out of Hospital at 30 days between the two arms or in all-cause mortality at 30 days.

## Online Training Modules

Click the pictures below to be directed to CLARITY's training modules. These include Background & Rationale, ARB Guidance and Operations.

**CLARITY**  
Controlled evaluation of Angiotensin Receptor Blockers for COVID-19 respiratory disease

**BACKGROUND AND RATIONALE**

Sound on

**CLARITY**  
Controlled evaluation of Angiotensin Receptor Blockers for COVID-19 respiratory disease

**OPERATIONS**

Sound on

**CLARITY**  
Controlled evaluation of Angiotensin Receptor Blockers for COVID-19 respiratory disease

**ARB GUIDANCE**

Sound on

*'Endpoint & Trial Design' training module coming soon!*

### Project Timelines

<b>MAR 2020</b>	<i>Protocol Development</i>	<i>Done</i>
<b>MAY 2020</b>	<i>Study Set up Activities</i>	<i>Done</i>
<b>JUN 2020</b>	<i>First Site Activated</i>	<i>Done</i>
<b>AUG 2020</b>	<i>MRFF Funding Received</i>	<i>Done</i>
<b>SEP 2020</b>	<i>First Participant First Visit</i>	<i>Done</i>
<b>SEP 2020</b>	<b>All Sites Activated – India &amp; Australia</b>	
<b>SEP 2020</b>	<b>DSMB #1</b>	
<b>DEC 2020</b>	<b>Last Participant First Visit</b>	
<b>JAN 2021</b>	<b>All Primary Outcome Data</b>	
<b>JAN 2021</b>	<b>Primary Analysis &amp; Publication</b>	
<b>MAR 2021</b>	<b>Last Participant Last Visit</b>	
<b>MAR 2021</b>	<b>Database Lock &amp; All Sites Closed</b>	
<b>MAR 2021</b>	<b>Secondary Analyses &amp; Publication</b>	

